Responding to market feedback, Turon Medtech is continuing to develop Cytosafe; a solution designed to simplify biopsy procedures and enhance safety. Cytosafe aims to reduce contamination risk and ensure correct needle sizing. In 2025, the product was patented, marking a significant milestone in an ongoing development process that reflects Turon’s commitment to innovation and future-ready healthcare solutions.

To accelerate innovation, Turon Medtech established a dedicated research and development center in Halmstad in 2023. The facility features advanced in-house 3D printing capabilities using SLA (Stereolithography) and FDM (Fused deposition modeling) technologies, enabling rapid prototyping and small-scale production.

In 2022, Turon Medtech began a strategic program to redefine stereotactic- and tomobiopsy workflows. The focus is on improving safety and efficiency throughout the entire pathway, from screening to biopsy, while incorporating advanced technologies such as AI. These developments are a central part of Turon’s long-term vision to deliver innovative and dependable healthcare solutions.

After years of research, artificial intelligence began to be implemented in clinical mammography workflows around 2021. Based on deep learning, the technology provides risk scores, which estimate the likelihood of cancer for each case, and lesion markings, which highlight suspicious areas on the image to guide radiologists. Large scale studies show that AI can increase cancer detection by 20 – 30 percent while reducing unnecessary recalls, making the process both safer and more efficient. This is regarded as the next major step in the evolution of breast cancer screening.

To meet market demands, Cytoguide’s hand control was redesigned in 2020 with tactile feedback for precise manual positioning. In 2021, a major electronics upgrade followed, maintaining performance and preparing the system for future requirements.

In 2018, Turon Medtech developed additional needle holders to fully support both lateral and vertical vacuum-assisted biopsies, optimized for all major VAB needle types. In 2019, a lateral holder for fine- and core-needle biopsies was launched, broadening clinical flexibility and application.

By 2017, Cytoguide became fully compatible with tomosynthesis guided biopsies, 3D imaging instead of traditional 2D projections. This advancement reduced the risk of lesions being hidden by overlapping tissue and improved targeting accuracy, especially for small or subtle findings. At the same time, Turon introduced the Quick Mount Adapter system. The system aimed to simplify the handling of needle holders while also being transparent during tomosynthesis guided biopsies with both fine and core needles, streamlining procedures and increasing precision. Turon Medtech also expanded its internal capabilities with 3D printers for rapid prototyping, SLA (Stereolithography) and FDM (Fused deposition modeling) printing.

In 2016, Turon Medtech joined the PS Provider Group, marking a new chapter of strategic development and expanded resources. At this time, Jonas Lindquist gradually transitioned out of his operational role, ensuring a smooth handover. He continues at serve as a valued mentor, supporting Turon Medtech’s commitment to excellence and innovation.

In 2015, Turon Medtech introduced the third-generation Cytoguide, with a clear focus on user needs and biopsy workflow. The upgrade added new features to enhance safety, streamline procedures, and simplify operations. These improvements made the system more intuitive and efficient, reinforcing its global market position.

Digital breast tomosynthesis (DBT), also known as 3D mammography, emerged as an evolution of traditional 2D imaging. This technology creates thin sectional images of the breast, making it easier to detect small or hidden lesions, especially in dense breast tissue. The FDA approved the first commercial system in 2011, and major studies throughout the decade showed that DBT could increase cancer detection by 30 to 40 percent while simultaneously lowering the amount of false-positive results compared to 2D imaging. During the late 2000s and early 2010s, vacuum assisted.

The new millennium introduced digital mammography, approved by the FDA in 2000. Digital technology streamlined workflows, eliminated film processing, and enabled advanced image manipulation along with PACS (Picture Archiving and Communication Systems) archiving, used to store and share medical images electronically. The second generation Cytoguide evolved to integrate seamlessly with digital systems, ensuring continued leadership in precision biopsy. Turon Medtech strengthened global partnerships, collaborating with major players such as Siemens and further expanding its reach across the globe.

In 2000, Turon Medtech AB was established as an independent entity, breaking away from Turon AB under the leadership of Jonas Lindquist. With visionary drive and entrepreneurial spirit, Jonas transformed Turon Medtech into a thriving company, laying the foundation for its future growth and innovation in stereotactic breast biopsy solutions.

Throughout the 1990s, the first-generation analog Cytoguide system gained worldwide adoption, integrated into systems from leading manufacturers such as Planmed and Toshiba. Meanwhile, biopsy techniques advanced from fine needle aspiration to core biopsy, and later vacuum assisted biopsy (VAB). VAB uses a vacuum powered device to collect larger tissue samples. This method also enables percutaneous removal, meaning removal through the skin without open surgery, of suspicious calcifications and minimizes surgical interventions. The first vacuum assisted biopsy device received FDA approval in 1995. Its use expanded quickly in the United States, while spread in other regions was more gradual.

Amid Sweden’s national screening rollout, Inventor Björn Ericson together with Chief Physician Bjurstrand at Sahlgrenska University Hospital initiated development of Cytoguide—the world’s first automated positioning system for breast biopsy. The first prototype appeared in 1986, followed by global commercialization of the first generation in partnership with Philips in 1987. Cytoguide became a milestone in stereotactic biopsy, setting new standards for precision and efficiency.

Stereotactic breast biopsy, which uses three dimensional coordinates to sample non-palpable lesions, meaning small abnormalities that cannot be felt during a physical exam, was pioneered in Sweden alongside early screening programs. Karolinska Institutet in Stockholm led the world in clinical application, thanks to innovators Sven K. Franzén and Josef Zajicek, both renowned pathologists who advanced breast cancer diagnostics. The first stereotactic biopsy table was built in the early 1980s, reducing unnecessary surgery for benign findings, which are noncancerous tissue changes. The technique quickly spread internationally, with U.S. adoption in 1986 and 1987 directly influenced by Swedish expertise.

The 1970s marked a shift from diagnostic mammography to preventive screening. The HIP study in New York, a large clinical trial, showed that regular mammography could reduce breast cancer mortality by about 30 percent. Sweden emerged as a global leader: Bengt Lundgren’s low dose technique in Gävleborg minimized radiation exposure without compromising image quality, and László Tabár’s landmark Two County Trial (1977–1985), a randomized study involving thousands of women in two Swedish counties, demonstrated that organized screening programs significantly reduce breast cancer deaths. Sweden introduced nationwide breast cancer screening in 1986, supported by studies in Malmö, Stockholm, and Gothenburg, cementing its position at the forefront of screening innovation.

During the 1950s and 1960s, mammography evolved from basic X-ray images to dedicated high resolution breast imaging systems. Innovations by Robert Egan improved film techniques, enabling detection of small nonpalpable tumors. Advances such as xeromammography, a dry imaging process that offered clearer soft tissue contrast, and molybdenum based X-ray tubes, which provided optimal energy for breast tissue, dramatically enhanced image quality and established the basis for today’s reliable breast cancer diagnostics.

In 1913, German physician Albert Salomon captured the world’s first mammographic images by X-raying surgically removed breasts to study cancerous tissue. His pioneering work revealed how different breast tumors appeared on X-ray and how they spread to lymph nodes, laying the foundation for modern breast imaging.